Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Balance sheet by liuqingyan

VIEWS: 6 PAGES: 8

									IMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
Add; 04, Street 30/4, District 1, Cao Lanh town, Dong Thap
                                  CONSOLIDATED FINANCIAL STATEMENT
                                        Fiscal year ended on Dec 31, 2006

                                                 BALANCE SHEET

                                                                                               Unit: VND

         ASSETS                                      Code         2006                     2005

  A-     CURRENT ASSETS                              100         260,420,047,551         286,950,372,634

  I.     Cash and cash equivalents                   110          65,607,176,574          55,922,548,767
  1.     Cash                                        111          41,509,353,991          55,922,548,767
  2.     Cash equivalents                            112          24,097,822,583                       -

  II.    Short-term financial investment             120                       -                        -
  1.     Short-term investments                      121                       -                        -
  2.     Provisions for short-term investment        129                       -                        -

  III.   Receivables                                 130          56,766,743,946          81,187,597,523
   1.    Trade receivables                           131          49,833,173,710          42,123,576,746
   2.    Prepayments to suppliers                    132           6,259,254,430          33,880,599,711
   3.    Inter-company receivables                   133                       -                       -
         Receivables by progress of construction
  4.     projects                                    134                       -                       -
  5.     Other receivables                           135             925,304,382           5,183,421,066
  6.     Provision for bad debts                     139            (250,988,576)                      -

  IV.    Inventories                                 140         129,764,501,303         143,629,224,665
   1.    Inventories                                 141         130,013,512,727         144,272,625,280
   2.    Provision for inventory devaluation         149            (249,011,424)           (643,400,615)

  V.     Other current assets                        150           8,281,625,728           6,211,001,679
  1.     prepaid expenses                            151                       -                       -
  2.     VAT deductible                              152             308,287,529             862,373,695
         Tax and others receivables from the State
  3.                                                  154                     -                        -
  4.     Other current assets                         158         7,973,338,199            5,348,627,984
                      Assets                         Code         2006                     2005

  B-     NON-CURRENT ASSETS                          200          44,250,488,363          27,981,620,483

  I.     Long-term receivables                       210                       -                        -
  1.     Long-term trade receivables                 211                       -                        -
         Capital in the subsidiaries and legal
  2.     entities                                    212                       -                        -
  3.     Long-term inter-company receivables         213                       -
  4.     Other long-term receivables                 218                       -                        -

                                                     Page 6       64133948-a718-43e9-b61d-823867261557.xls
IMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
Add; 04, Street 30/4, District 1, Cao Lanh town, Dong Thap
                                  CONSOLIDATED FINANCIAL STATEMENT
  5.    Provision for long-term receivables          219              -                        -

  II.   Fixed assets                           210       35,068,221,174          22,667,607,084
  1.    Tangible fixed assets                  221       31,069,052,232          21,525,502,720
        Historical cost                        222       91,467,362,743          75,735,311,364
        Accumulated depreciation               223      (60,398,310,511)        (54,209,808,644)
  2.    Financial leased fixed assets          224                    -                       -
        Historical cost                        225                    -                       -
        Accumulated depreciation               226                    -                       -
  3.    Intangible fixed assets                227                    -                       -
        Historical cost                        228                    -                       -
        Accumulated depreciation               229                    -                       -
  4.    Construction in progress               230        3,999,168,942           1,142,104,364

 III.   Investment property                    240                    -                        -
        Historical cost                        241                    -                        -
        Accumulated depreciation               242                    -                        -

  IV.   Long-term financial investments        250        1,574,500,000           1,023,500,000
   1.   Investment in subsidiaries             251                    -                       -
   2.   Investment in joint-ventures           252          182,000,000             182,000,000
   3.   Other long-term investments            258        1,392,500,000             841,500,000
   4.   Provision for long-term investments    259                    -                       -

  V.    Other non-current assets               260        7,607,767,189           4,290,513,399
  1.    Long-term prepaid expenses             261        6,642,045,158           4,290,513,399
  2.    Deferred corporate tax                 262          965,722,031                       -
  3.    Other non-current assets               268                    -                       -

        Total Assets                           270      304,670,535,914         314,931,993,117

  LIABILITIES AND OWNER'S EQUITY               Code       2006                    2005

  A-    Liabilities                            300       70,494,879,299         146,124,725,185

  I.    Current liabilities                    310       70,008,583,006         141,231,971,938
  1.    Short-term loans and debts             311        4,051,816,145          75,577,731,937
  2.    Trade payables                         312       30,919,971,803          44,941,277,534
  3.    Prepaid from customers                 313       11,092,439,414           5,238,642,905
  4.    Taxes and obligations to the state     314        4,852,393,722           3,741,591,511
  5.    Payables to employees                  315        3,586,033,808           7,484,785,989
  6.    Accrual expenses                       316        9,657,220,309           3,633,923,539
  7.    Inter-company payables                 317                    -                       -
        Payables to progress of construction
   8.   projects                               318                    -                       -
   9.   Other payables                         319        5,848,707,805             614,018,523
  10.   Provision for short-term payables      320                    -                       -


                                               Page 7    64133948-a718-43e9-b61d-823867261557.xls
IMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
Add; 04, Street 30/4, District 1, Cao Lanh town, Dong Thap
                                  CONSOLIDATED FINANCIAL STATEMENT

  II.   Long-term liabilities                     320         486,296,293            4,892,753,247
  1.    Long-term trade payables                  331                   -                        -
  2.    Long-term inter-company payables          332                   -                        -
  3.    Other long-term payables                  333         105,000,000            2,105,000,000
  4.    Long-term loans and debts                 334                   -            2,566,681,602
  5.    Deferred corporate tax payable            335                   -                        -
  6.    Unemployment allowances                   336         381,296,293              221,071,645
  7.    Provision for long-term payables          337                   -                        -


  B-    Owner's equity                            400      234,175,656,615         168,807,267,932

   I.   Owner's equity                            410      232,807,346,999         165,751,987,040
   1.   Capital                                   411       84,000,000,000          64,000,000,000
   2.   Capital surplus                           412       80,931,321,250          51,650,000,000
   3.   Other sources of capital                  413        1,936,631,314
   4.   Treasury shares                           414                    -                       -
   5.   Differences on asset revaluation          415                    -                       -
   6.   Foreign exchange rate differences         416                    -                       -
   7.   Business investment funds                 417       19,112,486,185          28,371,133,263
   8.   Financial reserve fund                    418        7,762,016,503           5,304,813,583
   9.   Other funds                               419                    -                       -
  10.   Retained earnings                         420       39,064,891,747          16,426,040,194
  11.   Construction investment fund              421                    -                       -

  II.   Other capital and funds                   430        1,368,309,616           3,055,280,892
  1.    Bonus and welfare fund                    431        1,368,309,616           3,055,280,892
  2.    Expenditure resources                     432                    -                       -
        Expenditure resources turned into fixed
  3.    assets                                    433                     -                       -

        TOTAL LIABILITIES AND OWNER'S
        EQUITY                                    440      304,670,535,914         314,931,993,117

                                   OFF-BALANCE SHEET ACCOUNTS

        Items                                                2006                    2005

  1.    Leased assets                                                     -                       -
  2.    Material, merchandize kept for outwork                            -                       -
  3.    Goods on consignment                                              -                       -
  4.    Processed bad debts                                               -                       -
  5.    Other foreign currencies
        USD                                                         5,207.80          1,074,429.01
        EUR                                                           530.16                630.84
        …                                                                  -                     -


                                                  Page 8    64133948-a718-43e9-b61d-823867261557.xls
    IMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
    Add; 04, Street 30/4, District 1, Cao Lanh town, Dong Thap
                                      CONSOLIDATED FINANCIAL STATEMENT
      6.    Forecast for non-productive projects                             -                        -




________________                                        _______________________
     Tran Hoai Hanh                                         Luu Thi Hanh        Nguyen Quoc Dinh
     Tabulator                                             Chief Accountant    Vice General Director




                                               Page 9           64133948-a718-43e9-b61d-823867261557.xls
    IMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY


                                    CONSOLIDATED FINANCIAL STATEMENT
                                        Fiscal year ended on Dec 31, 2006

                                               INCOME STATEMENT
                                            Fiscal Year 31, December 2006

                                                                                                    Unit: VND

       NO                       Items                   Code                2006                 2005

       1.    Revenue                                        01       527,283,500,415          339,164,891,589
       2.    Net deductions                                 03         1,877,480,946            1,830,445,920
       3.    Net revenue                                    10       525,406,019,469          337,334,445,669
       4.    Cost of goods sold                             11       367,260,277,211          217,980,921,368
       5.    Gross profit                                   20       158,145,742,258          119,353,524,301
       6.    Financial incomes                              21         1,429,541,935              791,036,638
       7.    Financial expenses                             22         3,757,066,201            8,956,887,169
             of which: interest expense                     23         2,382,718,210            7,626,731,508
       8.    Sale and marketing expenses                    24        98,699,233,432           73,245,520,787
       9.    Administration expenses                        25        12,813,109,076            8,035,670,785
       10.   Net profit from operating activities           30        44,305,875,484           29,906,482,198
       11.   Other incomes                                  31         4,631,724,245            2,118,977,629
       12.   Other expenses                                 32         1,823,997,231            2,017,820,870
       13.   Other profit                                   40         2,807,727,014              101,156,759
       14.   Total accounting profit before tax             50        47,113,602,498           30,007,638,957
       15.   Current corporate tax                          51         5,803,611,226            3,514,598,763
       16.   Deferred corporate tax                         52          (965,722,031)                       -
       17.   Profit after tax                               60        42,275,713,303           26,493,040,194
       18.   Earning per share                              70                 5,563                    5,801




________________                                                   _______________________
     Tran Hoai Hanh                                                Luu Thi Hanh     Nguyen Quoc Dinh
     Tabulator                                                     Chief Accountant Vice General Director




                                                        Page 10             64133948-a718-43e9-b61d-823867261557.xls
IMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
Add    No. 4, 30/4 Street, Ward 1, Cao Lanh Town, Dong Thap
                             CONSOLIDATED FINANCIAL STATEMENT
                                 Fiscal year ended on Dec 31, 2006

                                       CASH FLOW STATEMENT
                                             (Indirect method)
                                      Fiscal Year 31, December 2006

                                                                                  Unit: VND

                    Items                         Code          2006                      2005

 I.    Cash flows from operation
 1.    Profit before tax                           01           47,113,602,525          30,007,638,957
 2.    Adjustments
  -    Depreciation of fixed assets                02            6,624,801,258           5,984,697,612
  -    Provisions                                  03             (143,400,615)            643,400,615
  -    Gain/loss from foreign exchange             04                        -                       -
       differences
  -    Gain/loss from investing activities         05             (178,095,238)                      -
  -    Loan interest expenses                      06            2,382,718,210           7,626,731,508
 3.    Operating profit before changes of
       working capital
                                                   08           55,799,626,140           44,262,468,692
  -                                                09           22,099,240,952          (25,868,927,645)
       Increase/decrease of accounts receivable
  -    Increase/decrease of inventories            10           14,259,112,553            1,166,515,367
  -    Increase/decrease of accounts payable       11           (2,791,329,806)         (17,709,040,913)
  -    Increase/decrease of prepaid expenses       12           (2,351,531,759)             104,341,284
  -    Loan interest already paid                  13           (2,382,718,210)          (7,626,731,508)
  -    Corporate tax already paid                  14           (4,549,529,912)          (4,640,259,793)
  -    Other operating gains                       15              372,180,000           (3,676,412,653)
  -    Other operating expenses                    16           (8,846,654,620)           2,000,000,000
       Net cash flows from operating               20           71,608,395,338          (11,988,047,169)
       activities
 II.   Cash flows from investing activities
 1.    Purchases and construction of fixes
       assets and other long term assets
                                                   21          (19,025,415,348)          (6,379,580,414)
 2.    Gains from disposals and liquidation of     22              178,095,238                        -
       fixed assets and other long term assets
 3.    Loans given and purchases of debt           23                        -                        -
       instruments and other entities
 4.    Recovery of loans and disposals of debt     24                        -                        -
       instruments and other entities
 5.    Investment into other entities              25             (551,000,000)           (314,000,000)
 6.    Withdrawals of investment in other          26                        -                       -
       entities

                                                  Page 11       64133948-a718-43e9-b61d-823867261557.xls
     IMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
     Add    No. 4, 30/4 Street, Ward 1, Cao Lanh Town, Dong Thap
                                    CONSOLIDATED FINANCIAL STATEMENT
       7.   Receipts of loan interests, dividends and 27                   -                              -
            profit shared
            Net cash flows from investing activities  30     (19,398,320,110)               (6,693,580,414)
                              Items                           2006                           2005

      III. Cash flows from financing activities
       1. Gain from stock issuance and capital         31           38,023,149,973          70,740,219,658
           contribution from shareholders
       2. Repayment for capital contributions and
           re-purchases of stocks already issued
                                                       32                        -                       -
       3.                                              33           52,037,526,571         113,566,763,605
            Short-term and long-term loans received
       4.   Loan principal amounts repaid              34          (126,130,123,965)      (103,897,048,221)
       5.   Payments for financial leasehold assets    35                         -                      -
       6.   Dividend and profit already paid to the    36            (6,456,000,000)       (10,824,000,000)
            owners
            Net cash flows from financing             40            (42,525,447,421)        69,585,935,042
            activities
            Net cash flows during the year             50            9,684,627,807          50,904,307,459
            Beginning cash and cash equivalents        60           55,922,548,767           5,018,241,308
            Effects of fluctuations in foreign         61                        -                       -
            exchange rates
            Ending cash and cash equivalents           70           65,607,176,574          55,922,548,767
                                                                                 0                       -




________________                                            _______________________
     Tran Hoai Hanh                                             Luu Thi Hanh        Nguyen Quoc Dinh
     Tabulator                                                 Chief Accountant    Vice General Director




                                                      Page 12        64133948-a718-43e9-b61d-823867261557.xls
                             IMEXPHARM PHARMACEUTICAL JOINT STOCK
Company Name                 COMPANY
Code                         IMP (IMEXPHARM)
Add                          No. 4, 30/4 Street, Ward 1, Cao Lãnh Town, Dong Thap
Tel                          (84-67) 851 620
Fax                          (84-67) 853 106
Website                      www.imexpharm.com.vn
Email                        ifpi@hcm.vnn.vn
Registered capital           VND84 billion
                             Produce medicine for human, sterilization substance for human,
Business                     Produce traditional medicine
                             Trade medicine, drug, chemical, pharmaceutical material.
                             - Equitized on 25 July 2001
                             - Listed on 4 December 2006
Key Executives               - Chairman: Tran Thi Dao - 2,466,000 shares
                             Chief of Executive Officer: Tran Thi Dao
                             Deputy CEO: Tran Thai Hoang - 40,000 shares
                                            Nguyen Quoc Dinh - 70,000 shares
                                         Nguyen Thi Thu Hong - 40,000 shares
Equity Holding Information   - State: 28.29%
                             - Foreign: 13.22%
                             - Others: 58.49%
Auditor                      A&C Auditing and Consultancy Company Ltd.
Incorporation Date           28/09/1983
Number of Employees          605 (as of 31 December 2006)

								
To top